Novartis completed the acquisition of IFM Due from IFM Therapeutics for $835m.

Novartis, a Swiss multinational pharmaceutical company, completed the acquisition of IFM Due, a biopharmaceutical company developing small-molecule, orally available drug candidates, from IFM Therapeutics, a pharmaceutical company focused on developing biological treatments for autoimmune diseases, for $835m. "We have been steadfast in our belief that selectively targeting STING to block the cGAS-STING pathway has the potential to deliver a powerful therapeutic option for patients with serious chronic illnesses. Novartis has been an outstanding collaborator, and the program couldn't be in better hands. Today, as IFM Therapeutics marks the third major acquisition by a global pharmaceutical company, we cannot be more proud of our team's accomplishments and look forward to seeing our vision of precisely targeting the innate immune system to address a variety of serious inflammation-driven diseases become a reality for patients in need," H. Martin Seidel, IFM CEO.